IMR Press / FBL / Volume 24 / Issue 8 / DOI: 10.2741/4791
Open Access Article
Regulatory antibodies against GPCR in women ten years after early-onset preeclampsia
Show Less
1 Experimental and Clinical Research Center, a joint cooperation between Max-Delbrück-Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
2 DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
3 Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
4 Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
5 Berlin Institute of Health (BIH), Berlin, Germany
6 Radboud University Medical Center, Department of Cardiology, Nijmegen, The Netherlands
7 CellTrend GmbH, Luckenwalde, Germany
8 Saxenburgh Group, department cardiology, Hardenberg, The Netherlands
9 University of Mississippi Medical Center, Department of Pharmacology & Toxicology, Jackson, Mississippi, USA
10 Institute of Molecular Biology and Genetics of NASU, Kyiv, Ukraine
11 Department of Cardiology and Nephrology, HELIOS Klinikum Berlin, Berlin, Germany
Front. Biosci. (Landmark Ed) 2019, 24(8), 1462–1477; https://doi.org/10.2741/4791
Published: 1 June 2019
Abstract

Preeclampsia is associated with an increased cardiovascular risk later in life. Anti-GPCR autoantibodies have been shown to contribute to the development of cardiovascular disease. We investigated whether anti-GPCR autoantibodies are elevated in women with a history of early-onset preeclampsia 8-11 years postpartum, and whether they correlate with clinical outcomes. We investigated data from the Preeclampsia Risk EValuation in FEMales cohort, a retrospective matched case-control study. Anti AT1R-, beta1AR-, ETAR-, PAR1- and CXCR3- autoantibodies were determined in 485 samples by using commercially available ELISA. Women with the lowest combined levels of autoantibodies and a history of early preeclampsia had significantly higher SBP, DBP and MAP (all p<0.001) compared to the controls. The individual titer levels of autoantibodies were not different between controls and former early PE groups 8-11 years postpartum. In conclusion, regulatory autoantibodies alone are not sufficient to explain hypertension or other cardiovascular pathologic conditions, but together with other risk factors such as a previous hypertensive pregnancy, lower levels of autoantibodies are associated with increased blood pressure.

Keywords
Autoantibodies against GPCR
Preeclampsia
Adverse pregnancy outcome
Blood pressure
Cardiovascular risk
Figures
Figure 1.
Share
Back to top